Last reviewed · How we verify
medium itraconazole tablet
Itraconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity.
Itraconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity. Used for Blastomycosis, Histoplasmosis, Aspergillosis.
At a glance
| Generic name | medium itraconazole tablet |
|---|---|
| Also known as | medium dissolving itraconazole tablet |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Triazole antifungal |
| Target | Fungal CYP51 (lanosterol 14α-demethylase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Itraconazole is a triazole antifungal that selectively binds to fungal CYP51 enzyme, blocking the conversion of lanosterol to ergosterol, a critical sterol component of fungal cell membranes. This disruption leads to increased membrane permeability and fungal cell death. The drug has broad-spectrum activity against many fungal pathogens including Candida, Aspergillus, and dermatophytes.
Approved indications
- Blastomycosis
- Histoplasmosis
- Aspergillosis
- Onychomycosis (fungal nail infection)
- Oropharyngeal and esophageal candidiasis
Common side effects
- Nausea
- Abdominal pain
- Diarrhea
- Headache
- Rash
- Hypokalemia
- Hepatotoxicity
Key clinical trials
- Itraconazole Oral Absorption (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |